New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 8, 2023 - The FDA approved Regeneron’s Eylea (aflibercept), for treatment of retinopathy of prematurity (ROP).
Download PDF
Return to publications
